Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

As­traZeneca is work­ing on mov­ing its BTK in­hibitor Calquence in­to ear­li­er stages of man­tle cell lym­phoma, re­leas­ing what it calls pos­i­tive in­ter­im re­sults from a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER